A small scale MRC-funded pilot study into treating depression resistant to current therapies using psilocybin, the psychedelic compound of magic mushrooms, has found that it can be safely administered with appropriate support. This could pave the way for future randomised-controlled trials to establish the efficacy of the compound in treating this form of depression.